Protocols for Access to and Dose Selection of Selected IOP-Lowering Drugs
- Authors: Suchismita Acharya1, Peter G. Klimko2
-
View Affiliations Hide Affiliations1 AyuVis Research Inc., 3500 Camp Bowie Blvd, EAD #116J, Fort Worth, TX 76107, USA 2 Novartis Pharmaceuticals Corporation, Fort Worth, TX 76107, USA
- Source: Research Protocols for Ophthalmic Disease Mechanisms and Therapeutics: Glaucoma - Ocular Hypertension , pp 20-32
- Publication Date: August 2025
- Language: English
Protocols for Access to and Dose Selection of Selected IOP-Lowering Drugs, Page 1 of 1
< Previous page | Next page > /docserver/preview/fulltext/9789815324334/chapter-3-1.gif
Described herein are high-level protocols to access selected small molecules with IOP-lowering properties when topically dosed as ophthalmic formulations, as well as dose selection for evaluation in appropriate animal models. Sources are provided for commercially available drugs, and high-level synthetic protocols are described for agents that are not commercially available. The agents described are approved for use in humans or have demonstrated robust pre-clinical activity. These are drawn from a diverse range of pharmacological classes, such as prostaglandin analogs, betaadrenergic antagonists, carbonic anhydrase inhibitors, alpha-adrenergic agonists, and dual-activity prostaglandin-NO donors. Their physiological mechanisms of action have been characterized by the suppression of aqueous humor (AH) inflow, enhancement of AH conventional or uveoscleral outflow, and reduction of episcleral venous pressure.
-
From This Site
/content/books/9789815324334.chapter-3dcterms_subject,pub_keyword-contentType:Journal -contentType:Figure -contentType:Table -contentType:SupplementaryData105
